18 Apr 2012 - Congresos ALAT

Comments

Transcription

18 Apr 2012 - Congresos ALAT
Vareniclina
0.5 mg bid
n=129
Vareniclina
1 mg bid
n=821
Placebo
n=805
Náusea
16%
30%
10%
Insomnio
19%
18%
13%
Sueños anormales
9%
13%
5%
Constripación
5%
8%
3%
Flatulencia
9%
6%
3%
Vómito
1%
5%
2%
-Gonzales D JAMA. 2006; 296(1): 47-55.
- Jorenby D JAMA 2006; 296:56
2
3
4
5
6
RR=2,06
180
9
8
7
6
5
4
3
2
1
0
No
Fumadores
ExFumadores
1-14
15
Fumadores
Cigarrillos/Día
Eventos por 10.000 pessoas-ano
Riesgo Relativo(95% CI)
p<.001
10
161,2
160
140
120
116,6
RR=2,04
100
78,4
80
49
60
40
24
29,2
20
0
Não
Nunca
Sim
Ex-fumante
Fumante atual
-Miller et al. Am J Public Health. 2000;90:768-773.
7
QuarterWatchT: 2010 (Quarter 3)
8
9
10
18 Apr 2012
11
12
13
14
Publicación Julio 2011
15
16
Publicación Julio 2011
17
18
[7-22-2011]
Chantix may be associated with a small, increased risk of certain cardiovascular adverse
events in these patients—FDA communicated about this potential risk and labeling update in
the June 16, 2011 Drug Safety Communication. The absolute risk of cardiovascular adverse
events with Chantix, in relation to its efficacy, is small.
19
20
Christine E. Kistler, M.D., M.A.Sc. & Adam O. Goldstein, M.D., M.P.H.
21
Risk of cardiovascular serious adverse events associated with
varenicline use for tobacco cessation: systematic review and
meta-analysis J Prochaska , J Hilton BMJ 2012;344:e2856 /4 May 2012
22
Publicación Julio 2011
23

Similar documents

overview of medications to treat addiction in primary care

overview of medications to treat addiction in primary care 5. Anton RF, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005 Aug;25(4):349-57. 6. Feeney GF, et ...

More information